Naoyuki Iwahashi

Dr. Naoyuki Iwahashi

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2017 in Journal of Reproductive Immunology
Verified
Journal Article
Closed access
NINaoyuki Iwahashi
Naoyuki Iwahashi
MYMadoka Yamamoto
Madoka Yamamoto
SNSakiko Nanjo
Sakiko Nanjo
STSaori TOUJIMA
Saori TOUJIMA
SMSawako Minami
Sawako Minami
KIKazuhiko Ino
Kazuhiko Ino

18 July 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
NINaoyuki Iwahashi
Naoyuki Iwahashi
KSKazuko Sakai
Kazuko Sakai
TNTomoko Noguchi
Tomoko Noguchi
TYTamaki Yahata
Tamaki Yahata
HMHitomi Matsukawa
Hitomi Matsukawa
KIKazuhiko Ino
Kazuhiko Ino
Liquid biopsies of circulating tumor DNA (ctDNA) have recently been used as a non-invasive diagnostic tool for detecting tumor-specific mutations. We present a study of ctDNA liquid biopsies in gynecological cancer using an ultrasensitive next-generation sequencing-based method for ctDNA detection named CAncer Personalized Profiling by deep Sequencing (CAPP-Seq). We performed CAPP-Seq with plasma-ctDNA obtained from 16 patients with gynecological cancer. In all cases, at least one non-synonymous somatic mutation was detected in the ctDNA. In the pre-treatment ctDNA, 4 of 16, 4/16, 5/16, 2/16, 2/16, and 2/16 patients had TP53, KRAS, APC, PIK3CA, BRCA1, and EGFR mutations, respectively. MET gene copy-number gains were detected in the ctDNA of 2 of 16 patients, and FISH analysis of the paired tumor samples confirmed these results. In 2 neoadjuvant chemotherapy-treated ovarian cancer patients, the changes in gene mutation patterns were associated with the treatment response. These findings suggest that CAPP-Seq-based liquid biopsies can be used for the genetic characterization of independent gynecological cancers with high frequency, and might be clinically useful for non-invasive tumor genotyping and therapeutic response monitoring.

14 December 2020 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
NINaoyuki Iwahashi
Naoyuki Iwahashi
MIMidori Ikezaki
Midori Ikezaki
TNTaro Nishikawa
Taro Nishikawa
NNNorihiro Namba
Norihiro Namba
TOTakashi Ohgita
Takashi Ohgita
KNKazuchika Nishitsuji
Kazuchika Nishitsuji
Significance: Approximately 50 human diseases are associated with deposition of abnormally aggregated proteins that propagate in a prion-like manner. The tumor suppressor p53 forms amyloid-like aggregates; however, how p53 aggregates propagate remains unclear. Here, we identified heparan sulfate (HS), the common and major nonprotein component of in vivo deposits of various protein aggregates, as a mediator of prion-like propagation of p53 aggregates in cultured cells. Our immunohistochemical analysis showing codeposition of p53 and highly sulfated domains of HS in ovarian cancer tissues strongly support the role of HS-mediated propagation of p53 aggregates in cancer pathology. Accordingly, our results provide a mechanism of propagation of p53 aggregates that is mediated by HS. Elucidation of detailed biological relevance in cancer is warranted.

16 November 2020 in Cancers
Verified
Journal Article
Open access
PDF file
TNTomoko Noguchi
Tomoko Noguchi
NINaoyuki Iwahashi
Naoyuki Iwahashi
KSKazuko Sakai
Kazuko Sakai
KMKaho Matsuda
Kaho Matsuda
HMHitomi Matsukawa
Hitomi Matsukawa
KIKazuhiko Ino
Kazuhiko Ino
Liquid biopsies from circulating tumor DNA (ctDNA) have been employed recently as a non-invasive diagnostic tool for detecting cancer-specific gene mutations. Here, we show the comprehensive gene mutation profiles of ctDNA in 51 patients with different histological subtypes of stage I–IV ovarian cancer, and their association with clinical outcomes. The ctDNA extracted from pre-treatment patients’ plasma were analyzed using Cancer Personalized Profiling by Deep Sequencing targeting 197 genes. Of 51 patients, 48 (94%) showed one or more non-synonymous somatic mutations, including TP53 (37.3%), APC (17.6%), KRAS (15.7%), EGFR (13.7%), MET (11.8%), PIK3CA (11.8%), NPAP1 (11.8%), and ALK (9.8%). The most frequently mutated genes were as follows: TP53 in high-grade serous carcinoma (66.7%), APC in clear cell carcinoma (30.8%), PIK3CA in endometrioid carcinoma (40%), and KRAS in mucinous carcinoma (66.7%). Higher cell-free (cf)DNA concentration significantly correlated with worse progression-free survival (PFS) in all patients as well as stage III–IV patients (p = 0.01 and 0.005, respectively). Further, patients with any pathogenic mutations showed significantly worse PFS (p = 0.048). Blood tumor mutational burden detected from ctDNA did not significantly correlate with the histological subtypes or survival. Collectively, clinico-genomic profiles of individual ovarian cancer patients could be identified using ctDNA and may serve as a useful prognostic indicator. These findings suggest that ctDNA-based gene profiling might help in establishing personalized therapeutic strategies.

1 July 2022 in PNAS Nexus
Verified
Journal Article
Open access
PDF file
NINaoyuki Iwahashi
Naoyuki Iwahashi
MIMidori Ikezaki
Midori Ikezaki
YKYoshihiro Komohara
Yoshihiro Komohara
YFYukio Fujiwara
Yukio Fujiwara
TNTomoko Noguchi
Tomoko Noguchi
KNKazuchika Nishitsuji
Kazuchika Nishitsuji
Recent studies suggested that aggregates of mutant p53 proteins may propagate and impair normal p53 functioning in recipient cells. Our previous study showed that cancer cell-derived p53 aggregates that cells internalized interfered with p53-dependent apoptosis in recipient cells. However, involvement of p53 aggregate propagation in cancer pathology has not been fully elucidated. Here, we screened patients with high-grade serous ovarian carcinoma, which is characterized by an extremely high frequency of TP53 gene mutations, to show that patients with cytoplasmic p53 deposits have a poor prognosis compared with patients with complete p53 absence or strong nuclear p53 positivity. Cytoplasmic p53 in the patients with poor prognosis consisted of protein aggregates, which suggests that p53 aggregates are oncogenic drivers. Indeed, an inhibitor of p53 aggregation restored cellular apoptosis, a proper p53 function, in p53 aggregate-bearing patient-derived tumor organoids. In cell-based assays, endogenous and exogenous mutant p53 aggregates hindered chemotherapeutic activity of cisplatin, which depends on normal p53 functions. This inhibition was reduced by blocking p53 aggregation or internalization of p53 aggregates. Our study, thus indicates the involvement of p53 aggregate transmission in poor prognosis and in chemotherapy resistance in cancers.

19 October 2021 in Cancers
Verified
Journal Article
Open access
PDF file
NINaoyuki Iwahashi
Naoyuki Iwahashi
MIMidori Ikezaki
Midori Ikezaki
MFMasakazu Fujimoto
Masakazu Fujimoto
YKYoshihiro Komohara
Yoshihiro Komohara
YFYukio Fujiwara
Yukio Fujiwara
KNKazuchika Nishitsuji
Kazuchika Nishitsuji
High-grade serous ovarian carcinoma (HGSOC) is an epithelial cancer that accounts for most ovarian cancer deaths. Metabolic abnormalities such as extensive aerobic glycolysis and aberrant lipid metabolism are well-known characteristics of cancer cells. Indeed, accumulation of lipid droplets (LDs) in certain types of malignant tumors has been known for more than 50 years. Here, we investigated the correlation between LD accumulation and clinical prognosis. In 96 HGSOC patients, we found that high expression of the LD marker adipophilin was associated with poor progression-free and overall survival (p = 0.0022 and p = 0.014, respectively). OVCAR-3 ovarian carcinoma cells accumulated LDs in a glucose-dependent manner, which suggested the involvement of aerobic glycolysis and subsequently enhanced lipogenesis, with a result being LD accumulation. The acyl-CoA: cholesterol acyltransferase 1 inhibitor K604 and the hydroxymethylglutaryl-CoA reductase inhibitor pitavastatin blocked LD accumulation in OVCAR-3 cells and reduced phosphorylation of the survival-related kinases Akt and ERK1/2, both of which have been implicated in malignancy. Our cell-based assays thus suggested that enhanced aerobic glycolysis resulted in LD accumulation and activation of survival-related kinases. Overall, our results support the idea that cancers with lipogenic phenotypes are associated with poor clinical prognosis, and we suggest that adipophilin may serve as an independent indicator of a poor prognosis in HGSOC.